vs
Lakeside Holding Ltd（LSH）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是Lakeside Holding Ltd的1.3倍（$9.1M vs $7.0M），Lakeside Holding Ltd净利率更高（-22.6% vs -60.3%，领先37.8%），Lakeside Holding Ltd同比增速更快（95.0% vs -49.9%）
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
LSH vs PLX — 直观对比
营收规模更大
PLX
是对方的1.3倍
$7.0M
营收增速更快
LSH
高出145.0%
-49.9%
净利率更高
LSH
高出37.8%
-60.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.0M | $9.1M |
| 净利润 | $-1.6M | $-5.5M |
| 毛利率 | 27.2% | 49.4% |
| 营业利润率 | -21.3% | -51.1% |
| 净利率 | -22.6% | -60.3% |
| 营收同比 | 95.0% | -49.9% |
| 净利润同比 | 18.7% | -184.8% |
| 每股收益（稀释后） | $-0.08 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LSHPLX
| Q4 25 | $7.0M | $9.1M | ||
| Q3 25 | $6.1M | $17.9M | ||
| Q2 25 | $6.3M | $15.7M | ||
| Q1 25 | $3.8M | $10.1M | ||
| Q4 24 | $3.6M | $18.2M | ||
| Q3 24 | $4.1M | $18.0M | ||
| Q2 24 | — | $13.5M | ||
| Q4 23 | — | $10.5M |
净利润LSHPLX
| Q4 25 | $-1.6M | $-5.5M | ||
| Q3 25 | $-1.4M | $2.4M | ||
| Q2 25 | $-893.1K | $164.0K | ||
| Q1 25 | $-1.1M | $-3.6M | ||
| Q4 24 | $-1.9M | $6.5M | ||
| Q3 24 | $-1.3M | $3.2M | ||
| Q2 24 | — | $-2.2M | ||
| Q4 23 | — | $-6.0M |
毛利率LSHPLX
| Q4 25 | 27.2% | 49.4% | ||
| Q3 25 | 18.2% | 53.4% | ||
| Q2 25 | 26.7% | 62.5% | ||
| Q1 25 | 18.8% | 19.1% | ||
| Q4 24 | -1.2% | 78.7% | ||
| Q3 24 | 12.8% | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q4 23 | — | 15.5% |
营业利润率LSHPLX
| Q4 25 | -21.3% | -51.1% | ||
| Q3 25 | -20.8% | 11.9% | ||
| Q2 25 | -8.9% | 7.5% | ||
| Q1 25 | -28.2% | -41.0% | ||
| Q4 24 | -55.6% | 39.6% | ||
| Q3 24 | -32.5% | 22.2% | ||
| Q2 24 | — | -18.0% | ||
| Q4 23 | — | -53.5% |
净利率LSHPLX
| Q4 25 | -22.6% | -60.3% | ||
| Q3 25 | -22.2% | 13.2% | ||
| Q2 25 | -14.2% | 1.0% | ||
| Q1 25 | -28.2% | -35.8% | ||
| Q4 24 | -54.1% | 35.6% | ||
| Q3 24 | -32.7% | 18.0% | ||
| Q2 24 | — | -16.4% | ||
| Q4 23 | — | -57.6% |
每股收益（稀释后）LSHPLX
| Q4 25 | $-0.08 | $-0.06 | ||
| Q3 25 | $-0.09 | $0.03 | ||
| Q2 25 | $-0.11 | $0.00 | ||
| Q1 25 | $-0.14 | $-0.05 | ||
| Q4 24 | $-0.26 | $0.10 | ||
| Q3 24 | $-0.18 | $0.03 | ||
| Q2 24 | — | $-0.03 | ||
| Q4 23 | — | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6M | $14.7M |
| 总债务越低越好 | $2.4M | — |
| 股东权益账面价值 | $12.2M | $48.2M |
| 总资产 | $24.3M | $82.3M |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资LSHPLX
| Q4 25 | $1.6M | $14.7M | ||
| Q3 25 | $4.5M | $13.6M | ||
| Q2 25 | $5.0M | $17.9M | ||
| Q1 25 | $1.5M | $19.5M | ||
| Q4 24 | $1.1M | $19.8M | ||
| Q3 24 | $2.7M | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q4 23 | — | $23.6M |
总债务LSHPLX
| Q4 25 | $2.4M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $1.4M | — | ||
| Q1 25 | $774.2K | — | ||
| Q4 24 | $784.8K | — | ||
| Q3 24 | $589.9K | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
股东权益LSHPLX
| Q4 25 | $12.2M | $48.2M | ||
| Q3 25 | $7.0M | $52.9M | ||
| Q2 25 | $2.8M | $49.9M | ||
| Q1 25 | $749.8K | $45.2M | ||
| Q4 24 | $1.6M | $43.2M | ||
| Q3 24 | $3.6M | $32.4M | ||
| Q2 24 | — | $28.6M | ||
| Q4 23 | — | $33.6M |
总资产LSHPLX
| Q4 25 | $24.3M | $82.3M | ||
| Q3 25 | $18.6M | $82.3M | ||
| Q2 25 | $14.4M | $78.5M | ||
| Q1 25 | $9.9M | $73.9M | ||
| Q4 24 | $9.8M | $73.4M | ||
| Q3 24 | $10.8M | $61.6M | ||
| Q2 24 | — | $91.5M | ||
| Q4 23 | — | $84.4M |
负债/权益比LSHPLX
| Q4 25 | 0.20× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | 1.03× | — | ||
| Q4 24 | 0.48× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-453.5K | $2.0M |
| 自由现金流经营现金流 - 资本支出 | — | $1.6M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | — | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流LSHPLX
| Q4 25 | $-453.5K | $2.0M | ||
| Q3 25 | $-4.0M | $-3.7M | ||
| Q2 25 | $-483.7K | $-5.2M | ||
| Q1 25 | $-238.3K | $-5.1M | ||
| Q4 24 | $-530.2K | $4.0M | ||
| Q3 24 | $-1.4M | $4.1M | ||
| Q2 24 | — | $-3.6M | ||
| Q4 23 | — | $3.6M |
自由现金流LSHPLX
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | $-497.4K | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | $-560.5K | $3.6M | ||
| Q3 24 | $-1.4M | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q4 23 | — | $3.3M |
自由现金流率LSHPLX
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | -7.9% | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | -15.6% | 19.6% | ||
| Q3 24 | -34.5% | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q4 23 | — | 31.9% |
资本支出强度LSHPLX
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | 0.2% | 2.8% | ||
| Q1 25 | 0.0% | 3.0% | ||
| Q4 24 | 0.8% | 2.3% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q4 23 | — | 2.4% |
现金转化率LSHPLX
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
